INS and type 2 diabetes mellitus: Tirzepatide (compared to insulin degludec) has been shown to reduce intrahepatic triglycerides in type 2 diabetes [80], and may offer novel treatment options for patients with fatty liver disease (as previously described for selective GLP-1 RAs [81]).